A Phase 3, Multicenter, Randomized, Parallel-Group, Double-Masked, 2-Arm, Sham Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Participants with Dry Age-Related Macular Degeneration with Geographic Atrophy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515022-88-00

Acronym

ANX007-GA-02

Enrollment

125

Registered

2025-02-10

Start date

2025-03-03

Completion date

Unknown

Last updated

2025-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Age-Related Macular Degeneration (AMD) with geographic atrophy (GA)

Brief summary

Confirmed best corrected visual acuity (BCVA) ≥15-letter loss from baseline through the primary timepoint as assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) method. The primary timepoint is based on accumulation of the target event rate, but no earlier than Month 12 and no later than Month 18, French translation continuation

Detailed description

Incidence and severity of ocular and systemic treatment-emergent adverse events (TEAEs)

Interventions

DRUGANX007

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Confirmed best corrected visual acuity (BCVA) ≥15-letter loss from baseline through the primary timepoint as assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) method. The primary timepoint is based on accumulation of the target event rate, but no earlier than Month 12 and no later than Month 18, French translation continuation	—

Secondary

Measure	Time frame
Incidence and severity of ocular and systemic treatment-emergent adverse events (TEAEs)	—

Countries

Austria, Czechia, France, Germany, Hungary, Italy, Netherlands, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026